This thesis examines different risk factors, in relation to restenosis after Percutaneous coronary interventions (PCI), with its main focus on genetic markers. Restenosis is the main drawback of PCI. Genetic variance poses an opportunity to enhance stratification of individuals who will be more prone to develop restenosis. Restenosis is a multifactorial process, therefore only limited part of the number of candidate genes that are potentially involved in restenosis can be described. Since the inflammatory reaction is known to be highly important in restenosis, our study has its main focus on inflammatory markers. To examine various candidate genes and their polymorphisms we made use of the GENetic DEterminants of Restenosis (GENDER) study, a multicenter follow-up study, including 3,104 consecutive patients, who were successfully treated with PCI. In the different chapters we describe the study population and the clinical and genetic factors investigated. Furthermore, we made use of a mouse model to improve our understanding of restenosis. Our results have contributed to a better understanding of the restenotic process, they could provide novel therapeutic targets as well as contribute to development of improved risk stratification of patients who are scheduled for elective PCI, thereby creating the opportunity to individualize treatment in the future.LEI Universiteit LeidenNederlandse Hartstichting
Jacues H. de Nong Stichting
Medtronic Trading Nederland B.V.
St. Jude Medical Nederland
Sorin Group Nederland B.V.
Pfizer Nederland B.V.
Merck Sharp & Dohme B.V.
Boehringer Ingelheim B.V.
Bristol –Myers Squibb B.V.
AstraZeneca B.V.
Sankyo-pharma Nederland B.V.
Bayer B.V. HealthCareVasculaire biologie en interventi
